Brain Tumor, Pediatric Clinical Trial
Official title:
Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Supratentorial Brain Tumors
In this prospective, open, single-armed, multicenter, phase II study for application of 5-ALA in children and adolescents with supratentorial brain tumors 80 patients will be investigated. Primary objective of the study is to determine the safety of 5-ALA for fluorescence-guided resections in children and adolescents with supratentorial, intra-axial brain tumors. Secondary objectives are - to determine whether fluorescent tissue truly signifies tumor (positive predictive value) in various pediatric brain tumors - to determine the degree of tumor resection on early post-operative MRI - and to determine the pharmacokinetics of 5-ALA in this population.
In 2007, 5-aminolevulinic acid (5-ALA) was approved in Europe by the European Medicines Agency (EMA) (brand name: Gliolan®) for "the visualization of malignant tissue during surgery for malignant glioma (WHO III and IV) in adults." Similarly, approval for 5-ALA was granted by the FDA in 2017 as an "optical imaging agent indicated in patients with gliomas (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery" (brand name: Gliolan®). Goal of the study is to investigate if the use of 5-ALA is safe in children and get preliminary information on the type of paediatric brain tumors which are suitable for fluorescence-guided resection with 5-ALA. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06093165 -
RE-irradiation of Diffuse MIdline Glioma paTients
|
N/A | |
| Recruiting |
NCT05298995 -
GD2-CAR T Cells for Pediatric Brain Tumours
|
Phase 1 | |
| Recruiting |
NCT05709522 -
Neurocognitive and Psychosocial Outcomes Among Pediatric Brain Tumor and Blood Cancer Patients
|
||
| Recruiting |
NCT04722237 -
Acceptance and Commitment Therapy for Neuro-Oncology Wellbeing
|
N/A | |
| Recruiting |
NCT06309251 -
Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
|
||
| Recruiting |
NCT04670016 -
HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers
|
||
| Active, not recruiting |
NCT03086421 -
Social Emotional Development in Young Children With Cancer
|
||
| Active, not recruiting |
NCT03361033 -
Components of Social Functioning in Survivors of Pediatric Brain Tumors
|
||
| Active, not recruiting |
NCT04525014 -
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
|
Phase 1 | |
| Recruiting |
NCT05672043 -
Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China
|
||
| Recruiting |
NCT05553899 -
Utility of PET-MRI in Surveillance of Paediatric Brain Tumours
|
N/A | |
| Completed |
NCT03871686 -
Promotion of Well-being of Young Adult Brain Cancer Survivors
|
N/A | |
| Withdrawn |
NCT04019470 -
Immunomodulation Analysis of Radiation Therapy in Pediatric Malignant Brain Tumors
|
||
| Active, not recruiting |
NCT04023669 -
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
|
Phase 1 | |
| Suspended |
NCT05169944 -
Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors
|
Phase 1 |